Sarepta Therapeutics, Inc. or MorphoSys AG: Who Manages SG&A Costs Better?

SG&A Cost Management: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Over the past decade, MorphoSys AG and Sarepta Therapeutics, Inc. have demonstrated contrasting approaches to SG&A cost management.

From 2014 to 2023, MorphoSys AG's SG&A expenses grew by approximately 855%, starting from a modest $9.7 million to nearly $92.5 million. In contrast, Sarepta Therapeutics, Inc. saw a staggering increase of over 877%, with expenses rising from $49.3 million to $481.9 million. This significant difference highlights Sarepta's aggressive expansion strategy, which may be attributed to its rapid growth and increased market presence.

While both companies have seen substantial increases, MorphoSys AG's more conservative growth in SG&A expenses suggests a focus on cost efficiency, potentially offering a more sustainable financial model in the long run.